SCHEMBL4486366

SCHEMBL4486366

CCOC(=O)c1cc(C(=O)c2sc(Nc3ccc(OC)cc3)nc2N)on1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
NPC1 O15118 2/20 0.60
TUBB8B A6NNZ2 1/20 0.56
TUBB4A P04350 1/20 0.56
TUBB P07437 1/20 0.56
TUBB4B P68371 1/20 0.56
TUBB3 Q13509 1/20 0.56
TUBB2A Q13885 1/20 0.56
TUBB8 Q3ZCM7 1/20 0.56
TUBB6 Q9BUF5 1/20 0.56
TUBB2B Q9BVA1 1/20 0.56
TUBB1 Q9H4B7 1/20 0.56
SPHK2 Q9NRA0 1/20 0.56
SPHK1 Q9NYA1 1/20 0.56
ZAP70 P43403 1/20 0.56
DHODH Q02127 2/20 0.56
CDK5 Q00535 6/20 0.54
CDK5R1 Q15078 6/20 0.54
MAPT P10636 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478262 0.91 MAPT (0.54) MEN1KMT2ANPC1TUBB8BTUBB4A
SCHEMBL23930542 0.91 KDM4E (0.59) MEN1KMT2ANPC1ZAP70DHODH
SCHEMBL30210871 0.87 LMNA (0.55) MEN1KMT2ANPC1ZAP70DHODH
SCHEMBL31633449 0.87 DHODH (0.56) MEN1KMT2ANPC1ZAP70DHODH
SCHEMBL23930620 0.87 DHODH (0.56) MEN1KMT2ANPC1ZAP70DHODH
SCHEMBL30210901 0.85 KDM4E (0.55) MEN1KMT2ANPC1ZAP70DHODH
SCHEMBL30210844 0.84 DHODH (0.53) MEN1KMT2ADHODHMAPTLMNA
SCHEMBL4472482 0.82 MEN1 (0.81) MEN1KMT2ANPC1TUBB8BTUBB4A
SCHEMBL3819003 0.81 RAB9A (0.57) MEN1KMT2ANPC1DHODHCDK5
SCHEMBL4471723 0.81 CCNA2 (0.46) NPC1DHODHCDK5CDK5R1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US claimed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A MEN1 2737/4885KMT2A 2234/4885NPC1 2068/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A MEN1 2737/4885KMT2A 2234/4885NPC1 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.